Payment overview · 2025
General Payments
$804.97
49 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Earl Lane, MD
Allopathic & Osteopathic Physicians|Family Medicine · HERTFORD, NC · NPI 1023001500
Verified facts
What the public records show
CMS Open Payments records show Robert Earl Lane, MD received $804.97 in general payments during 2025 across 49 reported records.
ABBVIE INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $204.04 | 25.4% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.41 | 17.4% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $101.21 | 12.6% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.56 | 5.7% | 2 | 2025 |
| Endo USA, Inc. | Unresolved — no canonical attribution shown | $44.87 | 5.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.77 | 4.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.44 | 4.7% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $37.13 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.82 | 3.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.91 | 3.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $22.23 | 2.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.09 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.81 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.54 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.07 | 1.8% | 1 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $6.07 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $804.97 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $108.37 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.58 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $106.58 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.67 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.70 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.70 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.56 | 2 | 2025 |
Source payment records
|
|||||
| AVEED Normalized: aveed |
Biological | Endo USA, Inc. | $44.87 | 2 | 2025 |
Source payment records
|
|||||
| XIAFLEX Normalized: xiaflex |
Biological | Endo USA, Inc. | $44.87 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.77 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $37.44 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.82 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $6.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 165 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 698 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 697 | 169 |
| Amlodipine Besylate | Amlodipine Besylate | 577 | 132 |
| Omeprazole | Omeprazole | 539 | 139 |
| Losartan Potassium | Losartan Potassium | 408 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 384 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 367 | 106 |
| Gabapentin | Gabapentin | 366 | 103 |
| Hydrochlorothiazide | Hydrochlorothiazide | 338 | 86 |
| Lisinopril | Lisinopril | 331 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 77 |
| Metformin Hcl | Metformin Hcl | 275 | 72 |
| Metformin Hcl Er | Metformin Hcl | 272 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 262 | 66 |
| Furosemide | Furosemide | 249 | 66 |
| Tramadol Hcl | Tramadol Hcl | 245 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 230 | 65 |
| Trazodone Hcl | Trazodone Hcl | 211 | 55 |
| Allopurinol | Allopurinol | 184 | 45 |
| Montelukast Sodium | Montelukast Sodium | 173 | 47 |
| Simvastatin | Simvastatin | 170 | 46 |
| Carvedilol | Carvedilol | 168 | 41 |
| Potassium Chloride | Potassium Chloride | 166 | 38 |
| Eliquis | Apixaban | 165 | 29 |
| Glimepiride | Glimepiride | 155 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 132 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 24 |
| Irbesartan | Irbesartan | 131 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 17 |
| Jardiance | Empagliflozin | 120 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 33 |
| Alprazolam | Alprazolam | 117 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 27 |
| Finasteride | Finasteride | 113 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 33 |
| Celecoxib | Celecoxib | 109 | 21 |
| Telmisartan | Telmisartan | 109 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 31 |
| Ezetimibe | Ezetimibe | 102 | 21 |
| Sertraline Hcl | Sertraline Hcl | 100 | 24 |
| Bupropion Xl | Bupropion Hcl | 91 | 19 |
| Donepezil Hcl | Donepezil Hcl | 90 | 18 |
| Prednisone | Prednisone | 88 | 67 |
| Pregabalin | Pregabalin | 87 | 24 |
| Spironolactone | Spironolactone | 87 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 87 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 85 | 19 |
| Ozempic | Semaglutide | 84 | 21 |
| Atenolol | Atenolol | 81 | 20 |
| Meloxicam | Meloxicam | 81 | 24 |
| Clonazepam | Clonazepam | 80 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 24 |
| Xarelto | Rivaroxaban | 75 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 74 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 20 |
| Fenofibrate | Fenofibrate | 71 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 68 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Lorazepam | Lorazepam | 65 | 13 |
| Famotidine | Famotidine | 63 | 15 |
| Diazepam | Diazepam | 60 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 17 |
| Warfarin Sodium | Warfarin Sodium | 60 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 59 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 59 | 19 |
| Valsartan | Valsartan | 58 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 13 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Chlorthalidone | Chlorthalidone | 49 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 12 |
| Verapamil Er | Verapamil Hcl | 49 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 48 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 47 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 13 |
| Divalproex Sodium | Divalproex Sodium | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 19 |
| Ramipril | Ramipril | 42 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 40 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Rybelsus | Semaglutide | 40 | suppressed |
| Estradiol | Estradiol | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 15 |
| Buspirone Hcl | Buspirone Hcl | 37 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Nabumetone | Nabumetone | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 31 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 30 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ibu | Ibuprofen | 29 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | 11 |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Nystatin | Nystatin | 26 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Baclofen | Baclofen | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Livalo | Pitavastatin Calcium | 21 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 20 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 18 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $804.97 · 49 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APRETUDE, AREXVY, AVEED, Auvelity, BEYFORTUS, COMIRNATY, ELIQUIS, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, GEMTESA, JARDIANCE, Korlym, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, UBRELVY, UPTRAVI, VRAYLAR, XIAFLEX, XIFAXAN, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error